Recombine Endostatin

Small molecule

JJin Feng

Recombine Endostatin is one of 5 small molecule programs targeting Pharynx Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pharynx CancerActive, not recruiting

Pharynx CancerPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Pharynx Cancer

#DrugCompanyPhaseTrials

Alka-Seltzer

AAbbott

Approved

—2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—3

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 2

1 4

Docetaxel Micellar

Sanofi

Phase 2

1 5

Recombine Endostatin

JJin Feng

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pharynx Cancer1 trial

Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer

Unknown status·JJin Feng·Phase 2/3·NCT01689558·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Recombine Endostatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombine Endostatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombine Endostatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jin Feng company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: JJin Feng

Recombine Endostatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pharynx Cancer1 trial

References

Drug Info

Quick Facts

Related News